Younger age and female sex predict a better therapeutic response in HBeAg-positive chronic hepatitis B patients to entecavir therapy
Conclusion Two-year entecavir therapy has good biochemical and virologic responses; however, the rate of HBeAg loss is modest in HBeAg-positive CHB patients. A young age (i.e., ≤35 years) and female sex were also associated with a better serologic response.
Source: Advances in Digestive Medicine - Category: Gastroenterology Source Type: research
More News: Cirrhosis | Clinical Trials | Gastroenterology | Hepatitis | Hepatitis B | Study | Virology